Global Organ Transplant Market Report 2022: Rising Need for Innovative Tissue Transplantation Products and Organ Transplantation to Treat Organ Failure Propelling Sector
September 06, 2022 05:23 ET | Research and Markets
Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplant Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.A major element driving...
Surreal Photography Exhibit Brings Awareness
September 01, 2022 09:30 ET | Texas Organ Sharing Alliance
Austin, TX, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AUSTIN, TX (September 1, 2022) – A Central Texas couple who create fine-art surreal photographs is collaborating with the Austin-Bergstrom...
eledon-logo-1230.png
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences
August 29, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor...
The Worldwide Organ Transplant Diagnostics Industry is Expected to Reach $6 Billion by 2031
August 12, 2022 07:08 ET | Research and Markets
Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplant Diagnostics Market 2021-2031 by Offering, Transplant, Application, Technology, End User, and Region: Trend Forecast and Growth...
eledon-logo-1230.png
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
August 11, 2022 16:01 ET | Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating...
eledon-logo-1230.png
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 04, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical...
eledon-logo-1230.png
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
August 01, 2022 05:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
July 18, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:05 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
June 09, 2022 08:00 ET | Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...